We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
- Authors
Gamblin, T Clark; Egorin, Merrill J; Zuhowski, Eleanor G; Lagattuta, Theodore F; Herscher, Laurie L; Russo, Angelo; Libutti, Steven K; Alexander, H Richard; Dedrick, Robert L; Bartlett, David L
- Abstract
The pyrimidine analogue gemcitabine (2', 2'-difluorodeoxycitidine, dFdC) is active against pancreatic cancer, and its high clearance (CL(tb)) and low incidence of local toxicity make it an excellent candidate for evaluation as intraperitoneal (IP) therapy. We designed a dosing schema that used multiple sequential exchanges of a peritoneal dialysate containing dFdC in an effort to produce prolonged IP dFdC exposure.
- Publication
Cancer chemotherapy and pharmacology, 2008, Vol 62, Issue 4, p647
- ISSN
0344-5704
- Publication type
Journal Article
- DOI
10.1007/s00280-007-0647-9